

SWISS PHARMACEUTICAL COMPANY IBSA ACQUIRES PHARMASURE LTD, ESTABLISHING A STRONG PRESENCE IN THE UK MARKET

Lugano, May 19, 2022 – **IBSA Institut Biochimique SA**, the multinational pharmaceutical company based in Lugano, **acquired** 100% of the share capital of its **UK distributor, Pharmasure Ltd**. The purchase agreement was concluded in early May, and **the UK Company's name will change to IBSA Pharma Ltd**.

"IBSA and Pharmasure have been collaborating successfully for more than 20 years. The acquisition is part of the Group's strategy aimed at strengthening its commercial layout through the opening of its own subsidiaries. The UK is of strategic importance to the IBSA Group and acquiring Pharmasure will enable IBSA to further accelerate the growth of its fertility business as well as bringing its other therapy areas and new products into the IBSA Pharma portfolio". **Arturo Licenziati, President and CEO, IBSA Group.**

Pharmasure Ltd is a major player in the UK reproductive medicine market, enjoying great success through its marketing and distribution of the IBSA products.

"I have enjoyed working closely with IBSA for more than 20 years and am delighted with this acquisition. Thanks to this move, Pharmasure will grow faster with many more opportunities for the business and for our employees", **Terry Sullivan, Pharmasure Founder and Managing Director.**

Mr Sullivan, continues in his position post-acquisition as Managing Director.

Starting from now, he will be joined by **Steven Knapp** to whom full responsibility for managing the company will be transferred in the coming months.

IBSA Institut Biochimique SA

Headquartered in Lugano, IBSA Institut Biochimique SA is a multinational pharmaceutical Company founded in 1945. Today, its products are present in over 80 Countries on 5 continents, through the Company's 20 branches located in Europe, China and the United States. IBSA has a consolidated turnover of 700 million Swiss francs, and employs 2,000 people between headquarters, branches and production sites. IBSA Institut Biochimique SA holds 82 families of approved patents and others in development, as well as a vast portfolio of products, covering 10 therapeutic areas: endocrinology, reproductive medicine, dermoaesthetics, osteoarticular, pain and inflammation, dermatology, uro-gynaecology, cardio-metabolic, respiratory and consumer health. It is also the fourth largest operator worldwide in the area of Reproductive Medicine, and one of the world's leaders in the offer of hyaluronic acid-based products.

FOR INFORMATION TO THE PRESS

IBSA Press Office – Switzerland

Francesca Rossini – notizie@laboratoriodelleparole.net – mob: +41 77 417 93 72

IBSA Press Office – Italy

Valeria Riccobono – valeria.riccobono@noesis.net – mob: +39 392 962 5892

Ornella Reccia – ornella.reccia@noesis.net – mob. +39 329 393 1922

Job bag number: UKCOR00049

Date of preparation: May 2022

FOR FURTHER INFORMATION ABOUT IBSA

Website: www.ibsagroup.com

LinkedIn: www.linkedin.com/company/ibsa-sa

Facebook: www.facebook.com/ibsapharma